<code id='C54D3E6B8B'></code><style id='C54D3E6B8B'></style>
    • <acronym id='C54D3E6B8B'></acronym>
      <center id='C54D3E6B8B'><center id='C54D3E6B8B'><tfoot id='C54D3E6B8B'></tfoot></center><abbr id='C54D3E6B8B'><dir id='C54D3E6B8B'><tfoot id='C54D3E6B8B'></tfoot><noframes id='C54D3E6B8B'>

    • <optgroup id='C54D3E6B8B'><strike id='C54D3E6B8B'><sup id='C54D3E6B8B'></sup></strike><code id='C54D3E6B8B'></code></optgroup>
        1. <b id='C54D3E6B8B'><label id='C54D3E6B8B'><select id='C54D3E6B8B'><dt id='C54D3E6B8B'><span id='C54D3E6B8B'></span></dt></select></label></b><u id='C54D3E6B8B'></u>
          <i id='C54D3E6B8B'><strike id='C54D3E6B8B'><tt id='C54D3E6B8B'><pre id='C54D3E6B8B'></pre></tt></strike></i>

          Home / entertainment / focus

          focus


          focus

          author:explore    Page View:7

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In